Sempra (SRE) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
7 Jan, 2026Executive summary
Adjusted EPS for 2024 was $4.65, with 2025 guidance at $4.30–$4.70 and 2026 at $4.80–$5.30; long-term EPS growth target raised to 7–9% and a record $56B five-year capital plan announced, up 16% over the prior plan, with over half allocated to Texas and 90% to regulated utilities.
Growth strategy centers on expanding and modernizing energy networks, emphasizing safety, reliability, and affordability, with strong segment performance across Texas, California, and Infrastructure.
Sempra California received favorable 2024 General Rate Case decisions, enhancing investment visibility through 2027; Oncor’s System Resiliency Plan approved by PUCT.
Board approved a 15th consecutive annual dividend increase to $2.58 per share.
Sempra’s three growth platforms—California, Texas, and Infrastructure—serve nearly 40 million consumers and focus on grid modernization, safety, and clean energy.
Financial highlights
FY-2024 adjusted EPS was $4.65 (up from $4.61 in 2023); GAAP EPS was $4.42 (down from $4.79 in 2023); adjusted earnings reached $2.97B, GAAP earnings were $2.82B.
Q4 2024 adjusted earnings were $960M ($1.50/share), up from $719M ($1.13/share) in Q4 2023; Q4 2024 GAAP earnings were $665M ($1.04/share), down from $737M ($1.16/share) in Q4 2023.
2024 revenues totaled $13.19B, down from $16.72B in 2023; net cash from operating activities was $4.91B, down from $6.22B in 2023.
Capital expenditures for property, plant, and equipment were $8.22B in 2024, slightly down from $8.40B in 2023.
46% total shareholder return over the last three years.
Outlook and guidance
2025 EPS guidance revised to $4.30–$4.70 due to regulatory decisions and higher costs; 2026 guidance set at $4.80–$5.30, with long-term EPS growth rate raised to 7–9%.
Five-year capital plan (2025–2029) increased to $56B, with over 90% focused on regulated utility investments in Texas and California and a projected ~10% rate base CAGR.
Expect to exceed 9% EPS CAGR from 2025–2029, with Texas as a disproportionate contributor.
Targeting competitive total shareholder return and maintaining investment-grade credit ratings.
Targeting 2025 final investment decision for Port Arthur LNG Phase 2.
Latest events from Sempra
- $65B capital plan and record adjusted EPS drive sector-leading growth outlook.SRE
Q4 202526 Feb 2026 - Q2 2024 earnings rose to $713M, with strong Texas/California growth and major projects advancing.SRE
Q2 20242 Feb 2026 - Q3 EPS fell, but guidance and $3B equity plan reaffirmed; Texas and LNG drive growth.SRE
Q3 202416 Jan 2026 - Q1 2025 EPS up, guidance affirmed, and major asset sales and capital investment drive outlook.SRE
Q1 20258 Jan 2026 - Board refreshment, performance-based pay, and ambitious ESG targets headline the 2025 proxy.SRE
Proxy Filing1 Dec 2025 - Director nominee Jennifer M. Kirk will become CEO of Exubrion Therapeutics in May 2025.SRE
Proxy Filing1 Dec 2025 - Virtual meeting to elect 11 directors, ratify auditor, and approve executive pay.SRE
Proxy Filing1 Dec 2025 - Q2 2025 adjusted EPS held steady as utility growth, LNG progress, and guidance advanced.SRE
Q2 202523 Nov 2025 - Adjusted EPS up, major asset sale and Texas/LNG growth drive strong long-term outlook.SRE
Q3 20255 Nov 2025